The Russian-developed drug is supplied with platinum in the form of microparticles. When exposed to the blood itself, it is activated in a cancerous tumor. As a result of innovative development, the entire organ is not fully integrated, and the complex of phenomena manifests itself minimally.

Oncology is also very common, which is currently underrepresented by the Russian Federation and the Russian Federation (project 22-15-00182), the drug will be in cases where it is already almost impossible to defeat the disease with the help of radiation therapy or surgery.

Developers from MIS gave the name riboplatin to the innovative drug, and in fact it combines the already well-known scientists of the antitumor cisplatin, including platinum, as well as riboflavin, better known as vitamin B2.

Riboplatin has a particularly dual effect – due to cisplatin, DNA molecules are bound in cancerous formations, which disrupts their development, and the second component, riboflavin, when exposed to the UV result of the formation frequency reaction.

Another important property of the Russian drug is its targeted action – it is activated by finding If it is undesirable and excessive, this date is not toxic to the body and has serious side effects associated with chiotherapeutic properties.

In the near future, they will begin testing the drug on animals in order to ensure safety and expected effectiveness, and the developers from MISIS themselves are measuring the full optimal volumes of components for their development.

Source: Tech Cult

Previous articleApple’s VP hinted at “new ties to Apple” in an interview before WWDC. Waiting for AR helmet
Next articleMTS began to collect money for the distribution of the Internet from users’ devices. The option costs 49 rubles per day
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.


Please enter your comment!
Please enter your name here